Clinical Research Directory
Browse clinical research sites, groups, and studies.
QTX3046 in Patients With KRAS G12D Mutations
Sponsor: Quanta Therapeutics
Summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Official title: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2024-05-30
Completion Date
2027-07-01
Last Updated
2025-07-25
Healthy Volunteers
No
Conditions
Interventions
QTX3046
QTX3046 will be administered at protocol defined dose.
Cetuximab
Cetuximab will be administered at protocol defined dose.
Locations (5)
South Texas Accelerated Research Therapeutics, LLC Midwest
Grand Rapids, Michigan, United States
Duke Cancer Center
Durham, North Carolina, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC San Antonio
San Antonio, Texas, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States